APA (7th ed.) Citation

Tateishi, K., Fujihashi, K., Yamamoto, N., Hasegawa, H., Ainai, A., Sato, K., . . . Asanuma, H. (2019). CpG ODN G9.1 as a novel nasal ODN adjuvant elicits complete protection from influenza virus infection without causing inflammatory immune responses. Vaccine, 37(36), 5382-5389. https://doi.org/10.1016/j.vaccine.2019.07.032

Chicago Style (17th ed.) Citation

Tateishi, Koichiro, et al. "CpG ODN G9.1 as a Novel Nasal ODN Adjuvant Elicits Complete Protection from Influenza Virus Infection Without Causing Inflammatory Immune Responses." Vaccine 37, no. 36 (2019): 5382-5389. https://doi.org/10.1016/j.vaccine.2019.07.032.

MLA (9th ed.) Citation

Tateishi, Koichiro, et al. "CpG ODN G9.1 as a Novel Nasal ODN Adjuvant Elicits Complete Protection from Influenza Virus Infection Without Causing Inflammatory Immune Responses." Vaccine, vol. 37, no. 36, 2019, pp. 5382-5389, https://doi.org/10.1016/j.vaccine.2019.07.032.